BlackRock Inc. bought a new position in Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 8,373,117 shares of the company's stock, valued at approximately $8,959,000. BlackRock Inc. owned about 4.12% of Lucid Diagnostics at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Centiva Capital LP bought a new position in shares of Lucid Diagnostics during the third quarter valued at approximately $25,000. Cubist Systematic Strategies LLC purchased a new stake in Lucid Diagnostics in the first quarter worth $39,000. Abel Hall LLC purchased a new position in Lucid Diagnostics during the 4th quarter valued at about $33,000. JPMorgan Chase & Co. lifted its position in Lucid Diagnostics by 71,026.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company's stock valued at $38,000 after acquiring an additional 32,672 shares during the period. Finally, Pine Valley Investments Ltd Liability Co boosted its position in shares of Lucid Diagnostics by 73.2% in the 1st quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company's stock worth $39,000 after purchasing an additional 14,487 shares in the last quarter. Hedge funds and other institutional investors own 74.01% of the company's stock.
Lucid Diagnostics Trading Down 1.2%
LUCD opened at $0.94 on Friday. Lucid Diagnostics Inc. has a 12-month low of $0.86 and a 12-month high of $1.63. The business's fifty day simple moving average is $0.98 and its 200-day simple moving average is $1.10. The company has a market capitalization of $190.94 million, a price-to-earnings ratio of -2.00 and a beta of 1.10.
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $1.47 million during the quarter, compared to the consensus estimate of $1.43 million. On average, equities research analysts predict that Lucid Diagnostics Inc. will post -0.23 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the stock. Weiss Ratings cut shares of Lucid Diagnostics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 18th. Ascendiant Capital Markets upped their target price on shares of Lucid Diagnostics from $9.00 to $9.25 and gave the company a "buy" rating in a report on Monday, June 8th. Wall Street Zen cut shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research note on Saturday, July 4th. Maxim Group decreased their target price on Lucid Diagnostics from $3.00 to $2.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Finally, BTIG Research reissued a "buy" rating and set a $2.50 price target on shares of Lucid Diagnostics in a report on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $4.19.
Check Out Our Latest Research Report on LUCD
About Lucid Diagnostics
(
Free Report)
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
Read More
Want to see what other hedge funds are holding LUCD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
